AEterna Zentaris (AEterna Zentaris) Revenue : $4.50 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris Revenue?

AEterna Zentaris's revenue for the three months ended in Dec. 2023 was $0.12 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $4.50 Mil. AEterna Zentaris's Revenue per Share for the three months ended in Dec. 2023 was $0.03. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.93.

Warning Sign:

AEterna Zentaris Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of AEterna Zentaris was -21.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was -24.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was -40.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was -24.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, AEterna Zentaris's highest 3-Year average Revenue per Share Growth Rate was 129.60% per year. The lowest was -91.20% per year. And the median was -18.20% per year.

AEterna Zentaris Revenue Historical Data

The historical data trend for AEterna Zentaris's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Revenue Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Revenue

Get a 7-Day Free Trial

0.53

3.65

5.26

5.64

4.50

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Revenue	Get a 7-Day Free Trial															2.49	2.13	2.25	-	0.12

Competitive Comparison of AEterna Zentaris's Revenue

For the Biotechnology subindustry, AEterna Zentaris's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Revenue distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Revenue falls into.

AEterna Zentaris Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.50 Mil.

AEterna Zentaris (NAS:AEZS) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

AEterna Zentaris Revenue Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (AEterna Zentaris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Revenue

Comparable Companies

Traded in Other Exchanges

ET8:Germany ET8:Germany AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.